

**MAIL STOP PCT**

IFW

Docket No. 284025US0X PCT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF: Beatrice SCHAACK, et al.


SERIAL NO: 10/563,011

GAU:

FILED: December 30, 2005

EXAMINER:

FOR: SMALL INTERFERING RNA SPECIES TO SUB-UNITS \$G(A), \$G(A)' AND \$G(B) OF THE KINASE PROTEIN CK2, AND THE APPLICATIONS OF THE SAME



**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97**

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

**REFERENCES**

- ☒ The applicant(s) wish to make of record the references cited in the International Search Report and listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

**RELATED CASES**

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

**CERTIFICATION**

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

**DEPOSIT ACCOUNT**

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon



Norman F. Oblon

Registration No. 24,618

**Corwin P. Umbach, Ph.D.**  
**Registration No. 40,211**

Surinder Sachar

Registration No. 34,423

Customer Number

**22850**

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Form PTO 1449  
(Modified)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.  
284025US0X PCTSERIAL NO.  
10/563,011

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

Beatrice SCHAACK, et al.

FILING DATE

December 30, 2005

GROUP

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	2002/0147163	10/10/2002	MCKAY, Robert et al.			
	AB	6 455 307	9/24/2002	MCKAY, Robert et al.			
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AL	00/63364	10/26/2000	WO		NO
	AM					
	AN					
	AO					

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

AP	ULLOA, Luis et al, "Depletion of Casein Kinase II By Antisense Oligonucleotide Prevents Neuritogenesis in Neuroblastoma Cells", The EMBO Journal, Oxford University Press, Vol. 12, No. 4, Pages 1633-1640, 1993
AQ	FAUST, Russell A. et al, "Antisense Oligonucleotides Against Protein Kinase CK2-alpha Inhibit Growth of Squamous Cell Carcinoma of The Head and Neck in Vitro", HEAD & NECK, Vol.22, No.4, Pages 341-346, July 2000
AR	VOORHOEVE, P. Mathijs et al, "Knockdown stands up", TRENDS in Biotechnology, Vol. 21, No.1, Pages 2-4, January 2003
AS	READ, Martin L. et al, "RNA-based therapeutic strategies for cancer", Expert Opinion on Therapeutic Patents, Vol. 13, No.5, Pages 627-638, 2003
AT	PARRISH, Susan et al, "Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference", Molecular Cell, Vol. 6, No.5, Pages 1077-1087, November 2000
AU	ELBASHIR, Sayda M. et al, "Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate", The EMBO Journal, Oxford University Press, Vol.20, No.23, Pages 6877-6888, 2001
AV	BRANTL, Sabine., "Antisense -RNA regulation and RNA interference", Biochimica et Biophysica Acta, Vol. 1575, No.1-3, Pages 15-25, 2002
AW	BUCHOU, Thierry et al, "La Proteine Kinase CK2, une enzyme qui cultive la difference", MEDECINE SCIENCES, Vol. 19, No. 6-7, Pages 709-716, 2003
AX	AHMED, Khalil et al, "Joining the cell survival squad: an emerging role for protein kinase CK2", TRENDS in Cell Biology, Vol. 12, No. 5, Pages 226-230, 2002
AY	VALERO, Emmanuelle et al, "Modulation of the Protein Kinase CK2 Activity by a Synthetic Peptide Corresponding to the N-Terminus of Its beta Regulatory Subunit", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol. 232, No. 1, Pages 178-182, 1997
AZ	<input type="checkbox"/> Additional References sheet(s) attached

Examiner

Date Considered

\*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.